These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 5348411

  • 21. Exploration of the anti-depressant potential of L-dopa.
    Sanghvi I, Urquiaga X, Gershon S.
    Psychopharmacologia; 1971; 20(2):118-27. PubMed ID: 5104531
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [In-vitro action of L-dopa (3-4 dihydroxyphenylalanine) on cerebral glutamate decarboxylase (GAD) and on -aminobutyric transaminase (GABA-T) in rats].
    Macaione S, Mattaliano G, Livrea P.
    Boll Soc Ital Biol Sper; 1972 May 15; 48(9):216-21. PubMed ID: 5070092
    [No Abstract] [Full Text] [Related]

  • 25. The action L-dopa on sexual behaviour of male rats.
    Da Prada M, Carruba M, Saner A, O'Brien A, Pletscher A.
    Brain Res; 1973 Jun 15; 55(2):383-9. PubMed ID: 4541349
    [No Abstract] [Full Text] [Related]

  • 26. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F, Bartholini G, Gaillard JM, Tissot R.
    Encephale; 1971 Jun 15; 60(3):189-209. PubMed ID: 5119348
    [No Abstract] [Full Text] [Related]

  • 27. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 15; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B, Steinhäusl H.
    Wien Med Wochenschr; 1972 Jun 17; 122(25):369-71. PubMed ID: 4558132
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ, Porter CC.
    J Pharmacol Exp Ther; 1970 Apr 17; 172(2):406-15. PubMed ID: 5441162
    [No Abstract] [Full Text] [Related]

  • 33. The influence of various pharmacological agents on the desynchronization produced by DOPA in the cerveau isolé preparation.
    Kadzielawa K, Widy-Tyszkiewicz E.
    Electroencephalogr Clin Neurophysiol; 1970 Mar 17; 28(3):266-72. PubMed ID: 4190531
    [No Abstract] [Full Text] [Related]

  • 34. The proportionate loss of L-3,4-dihydroxyphenylalanine and L-5-hydroxttryptophan decarboxylating activity in rat central nervous system following intracisternal administration of 5, 6-dihydroxytryptamine or 6-hydroxydopamine.
    Dairman W, Horst WD, Marchelle ME, Bautz G.
    J Neurochem; 1975 Apr 17; 24(4):619-23. PubMed ID: 1079044
    [No Abstract] [Full Text] [Related]

  • 35. The EEG effects of dopa in the rabbit depending upon the level of brain-stem section.
    Kadzielawa K.
    Arch Int Pharmacodyn Ther; 1974 Feb 17; 207(2):310-21. PubMed ID: 4597220
    [No Abstract] [Full Text] [Related]

  • 36. Effects of L-DOPA on the EEG and brain amines of unrestrained rats.
    Thut PD, Rech RH.
    Exp Neurol; 1972 Apr 17; 35(1):13-29. PubMed ID: 5026410
    [No Abstract] [Full Text] [Related]

  • 37. Effect of L-aromatic amino acid decarboxylase inhibition on metabolism of dihydroxyphenylalanine by isolated perfused rat liver.
    Tyce GM, Owen CA.
    Biochem Pharmacol; 1972 Nov 15; 21(22):2977-89. PubMed ID: 4649349
    [No Abstract] [Full Text] [Related]

  • 38. Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase.
    Bartholini G, Constantinidis J, Tissot R, Pletscher A.
    Biochem Pharmacol; 1971 Jun 15; 20(6):1243-7. PubMed ID: 5315769
    [No Abstract] [Full Text] [Related]

  • 39. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W, Eisenlohr JJ.
    Nervenarzt; 1974 Jan 15; 45(2):22-9. PubMed ID: 4601993
    [No Abstract] [Full Text] [Related]

  • 40. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W, Butz P, Wiesendanger M.
    Dtsch Z Nervenheilkd; 1970 Jan 15; 197(1):85-100. PubMed ID: 5522871
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.